Skip to content

Better Classification of Respiratory Amyloidosis

Towards a Better Classification of Respiratory Amyloidosis. Contribution of Proteomic Analysis Based on Tandem Mass Spectrometry

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05862961
Acronym
B-AR
Enrollment
70
Registered
2023-05-17
Start date
2023-05-15
Completion date
2026-05-15
Last updated
2023-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyloidosis

Keywords

respiratory amyloidosis, proteomic analysis

Brief summary

The B-AR project is based on a retrospective analysis of amyloidosis typing and the identification of their amylogenic protein.This work should be able to unite many clinicians, including pulmonologists and pathologists around a rare disease that still suffers from insufficient data.

Detailed description

The B-AR study will highlight the interest of proteomic analysis of amyloidosis compared to their identification by immunostaining. The objective is to reduce diagnostic wandering and to improve patient management. The typing of respiratory amyloidosis will allow a better characterization of the disease and thus, to propose a dedicated therapeutic management.

Interventions

None listed

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient \> to 18 years with amyloidosis on a histological sample of the tracheobronchial or pulmonary tree.

Exclusion criteria

* Subject receiving state medical aid * Subject deprived of freedom, or under a legal protective measure (example: patients under guardianship or curators)

Design outcomes

Primary

MeasureTime frameDescription
Number of cases with identification of the amylogenic protein in respiratory amyloidosis.1 day (at inclusion)Identification of amylogenic protein by Proteomic Analysis Based on Tandem Mass Spectrometry on histological sample of the tracheobronchial or pulmonary tree.

Secondary

MeasureTime frameDescription
Distribution and severity of amyloidosis1 day (at inclusion)association between typing and respiratory involvement

Contacts

Primary ContactYurdagül UZUNHAN, Pr,MD, PhD
yurdagul.uzunhan@aphp.fr01 48 95 52 80
Backup ContactMagali COLOMBAT, MD PhD
Colombat.Magali@iuct-oncopole.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026